REG - Hemogenyx Pharma Plc - Recruitment of Second Patient for Clinical Trials

Hemogenyx PharmaceuticalsAnnouncement

17/03/2025 07:15

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250317:nRSQ9006Aa&default-theme=true

RNS Number : 9006A  Hemogenyx Pharmaceuticals PLC  17 March 2025

 

17 March 2025

 

Hemogenyx Pharmaceuticals plc

 

("Hemogenyx Pharmaceuticals" or the "Company")

 

Recruitment of Second Patient for HG-CT-1 Clinical Trial

 

 

Hemogenyx Pharmaceuticals plc (LSE: HEMO) is pleased to announce the
recruitment of the second patient for its clinical trial of HG-CT-1, its
proprietary CAR-T cell therapy, for the treatment of relapsed or refractory
acute myeloid leukemia (R/R AML) in adults. This marks a significant step
forward in the Company's clinical development program and underscores the
progress toward delivering a potentially life-saving treatment for AML
patients with limited therapeutic options.

The manufacturing of HG-CT-1 for the second patient, carried out by the
Company's team of scientists and quality control professionals, is scheduled
to commence shortly.

Further updates on the clinical trial will be provided in due course.

 

Dr. Vladislav Sandler, CEO & Co-Founder of Hemogenyx Pharmaceuticals,
commented:

"The recruitment of the second patient is indicative of the promising results
of the clinical trial for HG-CT-1 thus far and represents another critical
step in advancing HG-CT-1 as a potential breakthrough treatment for relapsed
or refractory AML. This milestone reflects the dedication of our team and the
strength of our science, bringing us closer to addressing an urgent unmet
medical need."

 

Market Abuse Regulation (MAR) Disclosure

Certain information contained in this announcement would have been inside
information for the purposes of Article 7 of Regulation No 596/2014 (as it
forms part of UK domestic law by virtue of the European Union (Withdrawal) Act
2018) until the release of this announcement. The person responsible for
arranging for the release of this announcement on behalf of Hemogenyx
Pharmaceuticals plc is Dr Vladislav Sandler, Chief Executive Officer &
Co-Founder.

 

 

 

Enquiries:

 Hemogenyx Pharmaceuticals plc                                   https://hemogenyx.com (https://hemogenyx.com/)
 Dr Vladislav Sandler, Chief Executive Officer & Co-Founder      headquarters@hemogenyx.com (mailto:headquarters@hemogenyx.com)
 Peter Redmond, Director                                         peter.redmond@hemogenyx.com (mailto:peter.redmond@hemogenyx.com)
 SP Angel Corporate Finance LLP                                  Tel: +44 (0)20 3470 0470
 Matthew Johnson, Vadim Alexandre, Adam Cowl
 Peterhouse Capital Limited                                      Tel: +44 (0)20 7469 0930
 Lucy Williams, Duncan Vasey, Charles Goodfellow

 

About Hemogenyx Pharmaceuticals plc

Hemogenyx Pharmaceuticals is a publicly traded company (LSE: HEMO)
headquartered in London, with its US operating subsidiaries, Hemogenyx
Pharmaceuticals LLC and Immugenyx LLC, located in New York City at its
state-of-the-art research facility.

 

The Company is a clinical stage biopharmaceutical group developing new
medicines and treatments to treat blood and autoimmune diseases. Hemogenyx
Pharmaceuticals is developing several distinct and complementary product
candidates, as well as platform technologies that it uses as engines for novel
product development.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RESEAADKFSLSEAA